Clearmind Medicine spotlights new CMND-100 alcohol use disorder trial data in June 10 webinar
PUBT · 1d ago
Share
Listen to the news
- Clearmind Medicine scheduled a June 10, 2026 webinar to present new insights from its ongoing Phase I/IIa trial of CMND-100 for alcohol use disorder.
- Trial data will be discussed in the future during a live investigator Q&A with researchers from Yale and Johns Hopkins.
- Focus is an update on clinical progress for an oral, non-hallucinogenic MEAI-based candidate, not a product launch or commercial rollout.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050732PRIMZONEFULLFEED9732435) on June 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved